Claims for Patent: 8,026,278

Summary for Patent: 8,026,278

Title:	Inhibitors of pyruvate kinase as therapeutic agents for cancer
Abstract:	The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.
Inventor(s):	Smith; Brian R. (Lasalle, CA), Chan; Tak-Hang (Montreal, CA), Leyland-Jones; Brian (Montreal, CA)
Assignee:
Application Number:	11/915,664
Patent Claims:	1. A method of inhibiting a breast cancer cell growth in a subject comprising administering to the subject an effective amount of an inhibitor selected from the group consisting of: a compound of formula II: wherein, ##STR00015## X and Y represent H, halide, or alkyl group; A is ##STR00016## R and R' represent H, alkyl, or aryl or heteroaryl ester; R'' represents H, or alkyl, or aryl or heteroaryl ester; any isomers or salts thereof; with the proviso that the compound of formula II is not ##STR00017## wherein R.sub.a.dbd.H, (Z)--F, (Z)--Cl, (E)-Cl and (Z)--CH.sub.3; ##STR00018## 2. The method of claim 1, which further comprising administering a second chemotherapeutic agent. 3. The method of claim 2, wherein the second chemotherapeutic agent is selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2-chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin-dunomycin, dexamethosone, doxurubicin, docetaxol, trastuzumab, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCl, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interferon alfa n3, irinotecan, leucovorin calcium, leuprolide, levamisole, lomustine, inegestrol, melphalan, L-sarcosylin, melphalan hydrochloride, MESNA, mechlorethamine, methotrexate, mitomycin, mitoxantrone, mercaptopurine, paclitaxel, plicamycin, prednisone, procarbazine, streptozocin, tamoxifen, 6-thioguanine, thiotepa, vinblastine, vincristine and vinorelbine tartrate. 4. The method of claim 1, wherein the effective amount of the inhibitor is delivered by direct intravenous or intraarterial injection to a tumor, or using a delivery system, or administered orally in the form of a tablet, capsule or liquid. 5. The methods of claim 1, wherein the inhibitor is delivered using a delivery system. 6. The methods of claim 2, wherein the second chemotherapeutic agent is delivered using a delivery system. 7. The method of claim 5, wherein the delivery system is selected from the group consisting of micelles, liposomes, transdermal and inhalation. 8. The method of claim 1, wherein the compound of formula II is chosen from: ##STR00019## wherein, X and Y represent H, halide, or alkyl group; A is ##STR00020## R and R' represent CH.sub.3; R'' represents CH.sub.3 or C.sub.2H.sub.5; any isomers or salts thereof.

Details for Patent 8,026,278

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-03-29
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-03-29